Literature DB >> 17923611

Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment.

L A van de Pol1, W M van der Flier, E S C Korf, N C Fox, F Barkhof, P Scheltens.   

Abstract

OBJECTIVE: A large cohort of subjects with mild cognitive impairment (MCI) was categorized into tertiles based on hippocampal atrophy rates, as a proxy for Alzheimer-type pathology. We compared baseline clinical, neuropsychological, and MRI measures to characterize these MCI subgroups.
METHODS: Serial MRI data of 323 subjects with MCI (49% men; mean +/- SD age: 69 +/- 9 years), followed for 2 years in a clinical trial, were available. Baseline hippocampal and whole brain volumes (WBV) were measured, and hippocampal volume change was assessed. Baseline medial temporal lobe atrophy (MTA), white matter hyperintensities (WMH), and lacunes were rated visually. The cohort was categorized into tertiles based on hippocampal atrophy rates (absent, moderate, and severe).
RESULTS: Rates of hippocampal atrophy (%/year) were 0.0 +/- 0.8 in the absent, 1.7 +/- 0.4 in the moderate, and 3.6 +/- 1.0 in the severe (mean +/- SD) tertile. Older age and the APOE epsilon 4 allele were associated with higher hippocampal atrophy rates (p < 0.0001 and p = 0.015). General cognition deteriorated over the MCI groups (p < 0.0001), whereas, after adjustment for age and sex, episodic memory and executive function did not. Baseline hippocampal atrophy was associated with increasing atrophy rates (hippocampal volume: p = 0.025; MTA score: p = 0.008); in contrast, WBV, WMH, and lacunes, adjusted for age and sex, were not significantly associated with hippocampal atrophy rates.
CONCLUSIONS: In mild cognitive impairment (MCI), older age, poorer general cognition, hippocampal atrophy, and APOE epsilon 4 predict subsequent accelerated rates of hippocampal atrophy, suggestive of the accumulation of Alzheimer-type pathology, which may become clinically manifest in the future. These markers may improve identification of subjects with MCI at risk for Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923611     DOI: 10.1212/01.wnl.0000277458.26846.96

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.

Authors:  Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 2.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

3.  Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice.

Authors:  Huang Huang; Sipei Nie; Min Cao; Charles Marshall; Junying Gao; Na Xiao; Gang Hu; Ming Xiao
Journal:  Age (Dordr)       Date:  2016-07-21

Review 4.  Progression of atrophy in Alzheimer's disease and related disorders.

Authors:  Jennifer L Whitwell
Journal:  Neurotox Res       Date:  2010-03-30       Impact factor: 3.911

5.  Alzheimer disease: hippocampal volume loss and Alzheimer disease progression.

Authors:  Wiesje M van der Flier; Philip Scheltens
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

6.  Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Authors:  Gloria C Chiang; Philip S Insel; Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Paul M Thompson; Eric M Reiman; Clifford R Jack; Nick C Fox; William J Jagust; Danielle J Harvey; Laurel A Beckett; Anthony Gamst; Paul S Aisen; Ron C Petersen; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

Review 7.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

8.  Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Authors:  W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier
Journal:  Neurology       Date:  2009-09-22       Impact factor: 9.910

9.  Total antioxidant capacity of the diet and major neurologic outcomes in older adults.

Authors:  Elizabeth E Devore; Edith Feskens; M Arfan Ikram; Tom den Heijer; Meike Vernooij; Fedde van der Lijn; Albert Hofman; Wiro J Niessen; Monique M B Breteler
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

Review 10.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.